Zyprexa

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
26-02-2024
产品特点 产品特点 (SPC)
26-02-2024
公众评估报告 公众评估报告 (PAR)
03-07-2013

有效成分:

olanzapine

可用日期:

Eli Lilly Nederland B.V.

ATC代码:

N05AH03

INN(国际名称):

olanzapine

治疗组:

Psycholeptics

治疗领域:

Schizophrenia; Bipolar Disorder

疗效迹象:

Coated tabletsAdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.InjectionAdultsZyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate. Treatment with Zyprexa powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate.

產品總結:

Revision: 42

授权状态:

Authorised

授权日期:

1996-09-27

资料单张

                                60
B. PACKAGE LEAFLET
61
PACKAGE LEAFLET: INFORMATION FOR THE USER
ZYPREXA 2.5 MG COATED TABLETS
ZYPREXA 5 MG COATED TABLETS
ZYPREXA 7.5 MG COATED TABLETS
ZYPREXA 10 MG COATED TABLETS
ZYPREXA 15 MG COATED TABLETS
ZYPREXA 20 MG COATED TABLETS
olanzapine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What ZYPREXA is and what it is used for
2.
What you need to know before you take ZYPREXA
3.
How to take ZYPREXA
4.
Possible side effects
5.
How to store ZYPREXA
6.
Contents of the pack and other information
1.
WHAT ZYPREXA IS AND WHAT IT IS USED FOR
ZYPREXA contains the active substance olanzapine. ZYPREXA belongs to a
group of medicines
called antipsychotics and is used to treat the following conditions:
•
Schizophrenia, a disease with symptoms such as hearing, seeing or
sensing things which are not
there, mistaken beliefs, unusual suspiciousness, and becoming
withdrawn. People with this
disease may also feel depressed, anxious or tense.
•
Moderate to severe manic episodes, a condition with symptoms of
excitement or euphoria.
ZYPREXA has been shown to prevent recurrence of these symptoms in
patients with bipolar disorder
whose manic episode has responded to olanzapine treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZYPREXA
_ _
DO NOT TAKE ZYPREXA
•
If you are allergic (hypersensitive) to olanzapine or any of the other
ingredients of this medicine
(listed in section 6).
An allergic reaction may be recognised as a rash, itching, a swollen
face,
swollen lips or shortness of breath. If this 
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ZYPREXA 2.5 mg coated tablets
ZYPREXA 5 mg coated tablets
ZYPREXA 7.5 mg coated tablets
ZYPREXA 10 mg coated tablets
ZYPREXA 15 mg coated tablets
ZYPREXA 20 mg coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ZYPREXA 2.5 mg coated tablets
Each coated tablet contains 2.5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 102 mg
lactose monohydrate.
ZYPREXA 5 mg coated tablets
Each coated tablet contains 5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 156 mg
lactose monohydrate.
ZYPREXA 7.5 mg coated tablets
Each coated tablet contains 7.5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 234 mg
lactose monohydrate.
ZYPREXA 10 mg coated tablets
Each coated tablet contains 10 mg olanzapine.
Excipient with known effect: Each coated tablet contains 312 mg
lactose monohydrate.
ZYPREXA 15 mg coated tablets
Each coated tablet contains 15 mg olanzapine.
Excipient with known effect: Each coated tablet contains 178 mg
lactose monohydrate.
ZYPREXA 20 mg coated tablets
Each coated tablet contains 20 mg olanzapine.
Excipient with known effect: Each coated tablet conatins 238 mg
lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Coated tablet
ZYPREXA 2.5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4112”.
ZYPREXA 5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4115”.
ZYPREXA 7.5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4116”.
3
ZYPREXA 10 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4117”.
ZYPREXA 15 mg coated tablets
Elliptical, blue, coated tablets
_ _
debossed with “LILLY” and a numeric identicode “4415”.
ZYPREXA 20 mg coated tablets
Pink, elliptical, coated tablets
_ 
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 26-02-2024
产品特点 产品特点 保加利亚文 26-02-2024
公众评估报告 公众评估报告 保加利亚文 03-07-2013
资料单张 资料单张 西班牙文 26-02-2024
产品特点 产品特点 西班牙文 26-02-2024
公众评估报告 公众评估报告 西班牙文 03-07-2013
资料单张 资料单张 捷克文 26-02-2024
产品特点 产品特点 捷克文 26-02-2024
公众评估报告 公众评估报告 捷克文 03-07-2013
资料单张 资料单张 丹麦文 26-02-2024
产品特点 产品特点 丹麦文 26-02-2024
公众评估报告 公众评估报告 丹麦文 03-07-2013
资料单张 资料单张 德文 26-02-2024
产品特点 产品特点 德文 26-02-2024
公众评估报告 公众评估报告 德文 03-07-2013
资料单张 资料单张 爱沙尼亚文 26-02-2024
产品特点 产品特点 爱沙尼亚文 26-02-2024
公众评估报告 公众评估报告 爱沙尼亚文 03-07-2013
资料单张 资料单张 希腊文 26-02-2024
产品特点 产品特点 希腊文 26-02-2024
公众评估报告 公众评估报告 希腊文 03-07-2013
资料单张 资料单张 法文 26-02-2024
产品特点 产品特点 法文 26-02-2024
公众评估报告 公众评估报告 法文 03-07-2013
资料单张 资料单张 意大利文 26-02-2024
产品特点 产品特点 意大利文 26-02-2024
公众评估报告 公众评估报告 意大利文 03-07-2013
资料单张 资料单张 拉脱维亚文 26-02-2024
产品特点 产品特点 拉脱维亚文 26-02-2024
公众评估报告 公众评估报告 拉脱维亚文 03-07-2013
资料单张 资料单张 立陶宛文 26-02-2024
产品特点 产品特点 立陶宛文 26-02-2024
公众评估报告 公众评估报告 立陶宛文 03-07-2013
资料单张 资料单张 匈牙利文 26-02-2024
产品特点 产品特点 匈牙利文 26-02-2024
公众评估报告 公众评估报告 匈牙利文 03-07-2013
资料单张 资料单张 马耳他文 26-02-2024
产品特点 产品特点 马耳他文 26-02-2024
公众评估报告 公众评估报告 马耳他文 03-07-2013
资料单张 资料单张 荷兰文 26-02-2024
产品特点 产品特点 荷兰文 26-02-2024
公众评估报告 公众评估报告 荷兰文 03-07-2013
资料单张 资料单张 波兰文 26-02-2024
产品特点 产品特点 波兰文 26-02-2024
公众评估报告 公众评估报告 波兰文 03-07-2013
资料单张 资料单张 葡萄牙文 26-02-2024
产品特点 产品特点 葡萄牙文 26-02-2024
公众评估报告 公众评估报告 葡萄牙文 03-07-2013
资料单张 资料单张 罗马尼亚文 26-02-2024
产品特点 产品特点 罗马尼亚文 26-02-2024
公众评估报告 公众评估报告 罗马尼亚文 03-07-2013
资料单张 资料单张 斯洛伐克文 26-02-2024
产品特点 产品特点 斯洛伐克文 26-02-2024
公众评估报告 公众评估报告 斯洛伐克文 03-07-2013
资料单张 资料单张 斯洛文尼亚文 26-02-2024
产品特点 产品特点 斯洛文尼亚文 26-02-2024
公众评估报告 公众评估报告 斯洛文尼亚文 03-07-2013
资料单张 资料单张 芬兰文 26-02-2024
产品特点 产品特点 芬兰文 26-02-2024
公众评估报告 公众评估报告 芬兰文 03-07-2013
资料单张 资料单张 瑞典文 26-02-2024
产品特点 产品特点 瑞典文 26-02-2024
公众评估报告 公众评估报告 瑞典文 03-07-2013
资料单张 资料单张 挪威文 26-02-2024
产品特点 产品特点 挪威文 26-02-2024
资料单张 资料单张 冰岛文 26-02-2024
产品特点 产品特点 冰岛文 26-02-2024
资料单张 资料单张 克罗地亚文 26-02-2024
产品特点 产品特点 克罗地亚文 26-02-2024

搜索与此产品相关的警报

查看文件历史